#GLP1RAs
LightNews LightNews
med-office-j.bsky.social
【備忘】Oct.28

ACC HP “Latest in Cardiology”欄に「HFpEFにおけるフレイルとサルコペニア：GLP-1RAの考慮点」と題するレビュー。

全文🔗 x.gd/AqDMON
Frailty and Sarcopenia in HFpEF: Considerations for GLP1RAs - American College of Cardiology
GLP-1 receptor agonists help patients with obesity‑related HFpEF feel and function better but clinicians should monitor for frailty and sarcopenia.
x.gd
October 28, 2026 at 11:28 PM
zanchey.aus.social.ap.brid.gy
Drug company goes into competition with pharmacies

https://www.abc.net.au/news/2026-10-01/backlash-over-eli-lilly-mounjaro-delivery/107211964

I don't really care about this - lots of people on GLP1RAs shop around - but I do think it's quite a move to undercut your distributors
Doctors condemn big pharma's move to dispense GLP-1s to your door
Doctors and pharmacists criticise Eli Lilly's new online platform, LillyDirect, which will dispense certain medicines, starting with Mounjaro, directly to a patient's door.
www.abc.net.au
October 6, 2026 at 8:45 AM
theisn.org
𝗧𝗢𝗗𝗔𝗬: ISN North and East Asia Regional Board Webinar: "Transforming CKD Care: Integrating SGLT2 Inhibitors, nsMRAs, and GLP1Ras."

🗣️ Sydney Tang
👤 Hyeong Cheon Park
🗓️ January 20
🕓 8 am CET
🔗 Free registration: http://lite.spr.ly/6...
January 20, 2026 at 6:00 AM
theisn.org
𝗦𝗔𝗩𝗘 𝗧𝗛𝗘 𝗗𝗔𝗧𝗘 for the next ISN North and East Asia Regional Board Webinar: "Transforming CKD Care: Integrating SGLT2 Inhibitors, nsMRAs, and GLP1Ras."

🗣️ Sydney Tang
👤 Hyeong Cheon Park
🗓️ January 20
🕓 8 am CET
🔗 Free registration: lite.spr.ly/60033eUb
January 13, 2026 at 8:20 AM
gastroadvisor.bsky.social
GLP-1 RAs are linked to lower risk for major fractures, specifically hip, thoracic, and pelvic bones, among those with MASH. #GLP1RAs #bonehealth #DDW2026
https://www.gastroenterologyadvisor.com/reports/glp-1ras-may-reduce-fracture-risk-in-mash/
GLP-1 RAs May Reduce Fracture Risk in MASH
GLP-1 RA use is associated with reduced risk for hip, thoracic, and pelvic fractures among those with MASH.
www.gastroenterologyadvisor.com
May 5, 2026 at 5:15 PM
castltrastondrs.medsky.network
#Medsky🧪 #neurosky #pharmsky #publichealth While #GLP1RAs show considerable promise, they are currently not approved for the treatment of #bipolardisorder.
Abstract
September 14, 2025 at 12:57 PM
centinel.bsky.social
Al seguir tratamientos con agonistas GLP-1 la pérdida de masa muscular es relativamente modesta y mucho menor que la pérdida de grasa:
onlinelibrary.wiley.com/doi/10.1111/...
How do glucagon‐like Peptide‐1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta‐analysis
Glucagon-like peptide-1 receptor agonists (GLP1RAs) are used for the management of type 2 diabetes (T2DM) and obesity. GLP1RAs induce significant weight loss but concerns have been raised regarding t...
onlinelibrary.wiley.com
April 6, 2025 at 1:40 PM
easoobesity.bsky.social
New comment in Nature Reviews Endo (£)

Causes of sarcopenia and frailty in people taking GLP1RAs Nature Reviews Endocrinology
Causes of sarcopenia and frailty in people taking GLP1RAs - Nature Reviews Endocrinology
Medications based on glucagon-like peptide 1 pathways are an efficient drug treatment for people with obesity, often eliciting rapid and pronounced weight loss. However, concerns have been raised…
www.nature.com
July 11, 2026 at 9:57 AM
jamanetworkopen.com
In adults with obesity, type 2 diabetes, and OSA, initiation of incretin receptor agonists/GLP1RAs, particularly tirzepatide, was associated with decreased risk of CPAP use, hospitalization, and mortality compared with SGLT2Is. ja.ma/4jecC3O
Three graphs compare GLP-1RA and SGLT21 treatments. Graph A shows CPAP use, B shows all-cause mortality, and C shows all-cause hospitalization. Each graph plots probability over 400 days, with numbers at risk detailed below each graph. GLP-1RA is consistently slightly better.
December 23, 2025 at 2:30 PM
delta4ai.bsky.social
💙 World Heart Day 2025

Repositioned drugs like SGLT2i, GLP1RAs, MRAs & ERAs show strong cardiorenal benefits. At Delta4, we advance this field with computational & biological insights. Read our Proteomics viewpoint:
analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/...
September 29, 2025 at 8:15 AM
aguler.bsky.social
New in this version:
– Behavioral profiling that separates nausea from satiety in mice
– Expanded characterization of brain regions activated by small-molecule GLP1RAs
– Further mapping of a hedonic feeding circuit that blunts dopamine release
June 16, 2025 at 7:19 PM
aguler.bsky.social
You can read more about our findings here: www.biorxiv.org/content/10.1... Please send us feedback on how we can improve our manuscript. All this work was led by three very talented graduate students: Lizzie Godschall, Buğra Güngül and Isabelle Sajonia. 15/15
A Brain Reward Circuit Inhibited By Next-Generation Weight Loss Drugs
Glucagon-like peptide-1 receptor agonists (GLP1RAs) effectively reduce body weight and improve metabolic outcomes, yet established peptide-based therapies require injections and complex manufacturing....
www.biorxiv.org
December 18, 2024 at 5:39 PM
aguler.bsky.social
Curious how a single amino acid substitution made it all possible? Read on! Or you can skip to the full manuscript: www.biorxiv.org/content/10.1... Are we really calling these "Bluetorials"? 2/15
A Brain Reward Circuit Inhibited By Next-Generation Weight Loss Drugs
Glucagon-like peptide-1 receptor agonists (GLP1RAs) effectively reduce body weight and improve metabolic outcomes, yet established peptide-based therapies require injections and complex manufacturing....
www.biorxiv.org
December 18, 2024 at 5:39 PM
craigagoodman1.bsky.social
How do glucagon-like Peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis
onlinelibrary.wiley.com/doi/10.1111/...
How do glucagon‐like Peptide‐1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta‐analysis
Glucagon-like peptide-1 receptor agonists (GLP1RAs) are used for the management of type 2 diabetes (T2DM) and obesity. GLP1RAs induce significant weight loss but concerns have been raised regarding t...
onlinelibrary.wiley.com
April 4, 2025 at 5:55 PM
dermatologyadvisor.bsky.social
Several #dermatologic adverse effects have been associated with the use of #GLP1RAs for #WeightLoss.

Read our story below featuring expert commentary from Dr Joshua Zeichner, MD, from Mount Sinai and Dr Alice Mina, MD, from Emory University School of Medicine.
Dermatologic Outcomes of GLP-1 RA Use
Patients using GLP-1 RAs may experience dermatologic adverse side effects, including skin laxity, hair shedding, and facial deflation.
www.dermatologyadvisor.com
June 18, 2026 at 11:51 PM
renalurologynews.bsky.social
GLP-1 RAs are not linked to increased risks for most serious GI or hepatobiliary outcomes compared with oral diabetes medications.
www.renalandurologynews.com/news/glp1ras... #diabetes
GLP-1RAs Do Not Have Worse GI Safety Than Other Diabetes Medications
GLP-1 RAs are not linked to an increased risk for serious GI or hepatobiliary outcomes, compared with other diabetes medications.
www.renalandurologynews.com
October 23, 2025 at 2:04 PM
jbrianbyrd.bsky.social
Moreover, she used GLP1R pathway as an example of a success that keeps us humble

The 9% reduction in all cause mortality seen with GLP1RAs can't be attributed to treatment of diabetes per se

There are non-linear effects, can't be understood by individual genes,

#PSB25
January 5, 2025 at 8:24 PM
fperrywilson.bsky.social
Let's start with the good news. GLP1ras were associated with protean benefits (in addition to weight loss): less infection, less schizophrenia, less suicide, less lung disease, less alcohol use disorder, less acute kidney injury (#blesstheirhearts).
January 22, 2025 at 9:33 PM
4040rec.bsky.social
#weightlossmedications #obesity #weightmanagement #onlineprescribing #GLP1receptoragonists #GLP1RAs #Privateprescribingplatforms #GeneralPharmaceuticalCouncil #onlineprescribingplatforms #MHRA #LMCs #BMA #CQC #GLP1RAprescriptions #digitalhealthservices #nationalprescribingregistry
zurl.co/XFSNp
16-17 GLP-1 - Weight expectations
As an occupation at the very epicentre of healthcare, the nurse is a constant and iconic presence. In this edition of PharmaTimes, we demonstrate how this reassuring and essential presence within our ...
magazine.pharmatimes.com
October 28, 2025 at 9:55 AM
doctorajgu.medsky.social
www.acpjournals.org/doi/10.7326/...
The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity | Annals of Internal Medicine
Background: Glucagon-like peptide-1 receptor agonists (GLP1RAs) lead to substantial weight loss and pain reduction in persons with knee osteoarthritis and obesity. Objective: To evaluate the cost-effe...
www.acpjournals.org
September 15, 2025 at 11:12 PM
medicalxpress.com.web.brid.gy
Tirzepatide found to be more cost-effective than semaglutide in patients with knee osteoarthritis, obesity
A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs), semaglutide and tirzepatide, for patients with osteoarthritis and obesity compared with usual care, diet and exercise, and weight loss surgeries.
medicalxpress.com
September 15, 2025 at 9:31 PM
cynamon.bsky.social
The moral hazard case is that we do not address the root cause, because we can treat the outcome. E.g. we should still strive for walkable cities and better access to healthy food even with GLP1RAs. We should discourage smoking even if we can treat lung cancer.
December 8, 2024 at 8:48 PM
cynamon.bsky.social
Some day there will be the equivalent of GLP1Ras for treating stupid, and it will be incredible.
December 5, 2024 at 9:12 PM